PT  - JOURNAL ARTICLE
AU  - Chaguza, Chrispin
AU  - Coppi, Andreas
AU  - Earnest, Rebecca
AU  - Ferguson, David
AU  - Kerantzas, Nicholas
AU  - Warner, Frederick
AU  - Young, H. Patrick
AU  - Breban, Mallery I.
AU  - Billig, Kendall
AU  - Koch, Robert Tobias
AU  - Pham, Kien
AU  - Kalinich, Chaney C.
AU  - Ott, Isabel M.
AU  - Fauver, Joseph R.
AU  - Hahn, Anne M.
AU  - Tikhonova, Irina R.
AU  - Castaldi, Christopher
AU  - De Kumar, Bony
AU  - Pettker, Christian M.
AU  - Warren, Joshua L.
AU  - Weinberger, Daniel M.
AU  - Landry, Marie L.
AU  - Peaper, David R.
AU  - Schulz, Wade
AU  - Vogels, Chantal B.F.
AU  - Grubaugh, Nathan D.
TI  - Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
AID  - 10.1101/2022.01.22.22269660
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.22.22269660
4099  - http://medrxiv.org/content/early/2022/01/25/2022.01.22.22269660.short
4100  - http://medrxiv.org/content/early/2022/01/25/2022.01.22.22269660.full
AB  - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continues to shape the coronavirus disease 2019 (Covid-19) pandemic. The detection and rapid spread of the SARS-CoV-2 ‘ Omicron’ variant (lineage B.1.1.529) in Botswana and South Africa became a global concern because it contained 15 mutations in the spike protein immunogenic receptor binding domain and was less neutralized by sera derived from vaccinees compared to the previously dominant Delta variant. To investigate if Omicron is more likely than Delta to cause infections in vaccinated persons, we analyzed 37,877 nasal swab PCR tests conducted from 12-26 December 2021 and calculated the test positivity rates for each variant by vaccination status. We found that the positivity rate among unvaccinated persons was higher for Delta (5.2%) than Omicron (4.5%). We found similar results in persons who received a single vaccine dose. Conversely, our results show that Omicron had higher positivity rates than Delta among those who received two doses within five months (Omicron = 4.7% vs. Delta = 2.6%), two doses more than five months ago (4.2% vs. 2.9%), and three vaccine doses (2.2% vs. 0.9%). Our estimates of Omicron positivity rates in persons receiving one or two vaccine doses were not significantly lower than unvaccinated persons but were 49.7% lower after three doses. In comparison, the reduction in Delta positivity rates from unvaccinated to 2 vaccine doses was 45.6-49.6% and to 3 vaccine doses was 83.2%. Despite the higher positivity rates for Omicron in vaccinated persons, we still found that 91.2% of the Omicron infections in our study occurred in persons who were eligible for 1 or more vaccine doses at the time of PCR testing. In conclusion, escape from vaccine-induced immunity likely contributed to the rapid rise in Omicron infections.Competing Interest StatementNDG is a paid consultant for Tempus Labs and the National Basketball Association.Funding StatementThis work was supported by CTSA Grant Number TL1 TR001864 (R.E.), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.), and the Centers for Disease Control and Prevention (CDC) Broad Agency Announcement # 75D30120C09570 (N.D.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board from the Yale University Human Research Protection Program determined that obtaining de-identified test results linked to vaccination status and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not research involving human subjects (IRB Protocol ID: 2000031374).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors